Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacogenomics

Background:

• Single-agent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard for metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations (exon 19 deletions [ex19del] and L858R).
• Significant interpatient heterogeneity exists in treatment response and duration to EGFR TKIs.
• Predictive biomarkers are crucial for optimizing TKI therapy in NSCLC.

Purpose of the Study:

• To evaluate the predictive value of baseline characteristics and early circulating tumor DNA (ctDNA) dynamics for TKI response in NSCLC.
• To identify patient subgroups unlikely to benefit from monotherapy EGFR TKIs.
• To inform clinical trial enrollment for patients with poor predicted response.

Main Methods:

• Analysis of baseline patient characteristics including EGFR mutation status (ex19del, L858R), TP53 status, performance status, tumor burden, and baseline ctDNA levels.
• Monitoring of ctDNA dynamics during the initial days or weeks of TKI treatment.
• Correlation of these factors with treatment response and duration.

Main Results:

• Patients with EGFR ex19del, TP53 wild-type, good performance status, low tumor burden, and no baseline ctDNA show the best response to TKIs.
• Patients with EGFR L858R, mutated TP53, poor performance status, high tumor burden, and detectable baseline ctDNA are generally poor responders.
• Early ctDNA dynamics reliably identify patients unlikely to benefit from single-agent TKIs.

Conclusions:

• Baseline characteristics and early ctDNA dynamics are powerful predictors of TKI response in EGFR-mutated NSCLC.
• Patients identified as non-responders by early ctDNA dynamics are candidates for alternative treatment strategies, such as clinical trials combining TKIs with chemotherapy or antiangiogenic drugs.
• Personalized treatment approaches based on molecular profiling and early response assessment can improve outcomes in NSCLC.